Eliana Merle

Barclays | Healthcare

Eliana Merle is an analyst from Barclays specializing in the Healthcare sector. Ranked #1472 out of 4769 analysts, they have issued 46 stock ratings with a success rate of 78.36% and an average return of 26.28%.

Eliana Merle has a well-established track record, with 46 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 78.36% and an average return of 26.28%, underscoring their expertise and ability to identify winning opportunities for investors.

#1472

Out of 4769

46

Total Ratings

+78.36%

Success Rate

+26.28%

Average Return

Recent Ratings Analysis

SGMT

Sep 09, 2026

Target

$18.00

Current

$10.86

Performance

0.00%

Eliana Merle rated SGMT as Overweight on Sep 09, 2026, setting a price target of 18. Shares have remained stable near 10.86, leaving the 18 target still in play.

IONS

Sep 09, 2026

Target

$90.00

Current

$56.02

Performance

0.00%

On Sep 09, 2026, IONS was given a Overweight rating by Eliana Merle, with a target price of 90. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

MRNA

Aug 24, 2026

Target

$125.00

Current

$135.61

Performance

-2.36%

MRNA received a Equal-Weight rating from Eliana Merle on Aug 24, 2026, aiming for 125. Shares remained flat at 135.61, aligning with the neutral rating.

VRTX

Aug 05, 2026

Target

$617.00

Current

$521.12

Performance

7.49%

On Aug 05, 2026, Eliana Merle published a Overweight outlook on VRTX, with a target of 617. Shares gained 7.49%, underscoring the accuracy of the bullish outlook toward 617.

MDGL

Aug 03, 2026

Target

$962.00

Current

$546.66

Performance

13.41%

Eliana Merle on Aug 03, 2026 assigned MDGL a Overweight rating, with a price target of 962. The Buy call aligned well with market performance, producing a gain of 13.41%.

ALNY

Aug 03, 2026

Target

$450.00

Current

$258.00

Performance

17.10%

On Aug 03, 2026, Eliana Merle reaffirmed ALNY with a Overweight rating, targeting 450. The recommendation was supported by strong follow-through as the stock rose from 258 to 258.

QURE

Jul 30, 2026

Target

$60.00

Current

$45.97

Performance

8.96%

QURE was rated Overweight by Eliana Merle on Jul 30, 2026, with a price objective of 60. A bullish response from the market helped close the gap of 14.03 to the target.

SABS

Jun 24, 2026

Target

$13.00

Current

$3.48

Performance

-9.37%

On Jun 24, 2026, Eliana Merle initiated coverage on SABS with a Overweight rating and target of 13. The Buy call has yet to be validated as shares remain 9.52 away from the target.

GOSS

May 19, 2026

Target

$0.28

Current

$0.16

Performance

-19.79%

Eliana Merle issued a Underweight recommendation for GOSS on May 19, 2026, price target set at 0.28. The Sell call exposed risks of betting against momentum, as the stock rallied -19.79%.

MBX

May 12, 2026

Target

$70.00

Current

$62.91

Performance

70.12%

On May 12, 2026, MBX was evaluated by Eliana Merle, who gave a Overweight rating and target of 70. This case illustrates how a timely bullish rating can translate into tangible gains of 70.12%.

ASND

May 11, 2026

Target

$345.00

Current

$260.81

Performance

9.28%

Eliana Merle rated ASND as Overweight on May 11, 2026, setting a price target of 345. The call has proven timely, with shares rising 9.28% toward the price target of 345.

REGN

Apr 30, 2026

Target

$917.00

Current

$807.65

Performance

14.23%

On Apr 30, 2026, REGN was given a Overweight rating by Eliana Merle, with a target price of 917. The stock rallied 14.23% after the rating, narrowing the gap to the target of 917 and validating the bullish stance.

RARE

Apr 29, 2026

Target

$43.00

Current

$14.31

Performance

-40.82%

RARE received a Overweight rating from Eliana Merle on Apr 29, 2026, aiming for 43. The rating hasn’t played out as hoped, with the stock trading 40.82% below expectations.

APLS

Apr 01, 2026

Target

$41.00

Current

$41.03

Performance

1.58%

On Apr 01, 2026, Eliana Merle published a Equal-Weight outlook on APLS, with a target of 41. Sideways action left the Hold view intact, with no major move since 41.03.

INSM

Apr 01, 2026

Target

$237.00

Current

$128.80

Performance

-21.87%

Eliana Merle on Apr 01, 2026 assigned INSM a Overweight rating, with a price target of 237. The call has struggled to gain traction, with shares losing 21.87%.

BMRN

Mar 04, 2026

Target

$105.00

Current

$64.41

Performance

—

On Mar 04, 2026, Eliana Merle reaffirmed BMRN with a Overweight rating, targeting 105. Market indecision has kept the 105 target in a holding pattern.

TPG

Mar 02, 2026

Target

$69.00

Current

$48.91

Performance

10.58%

TPG was rated Overweight by Eliana Merle on Mar 02, 2026, with a price objective of 69. A bullish response from the market helped close the gap of 20.09 to the target.

TYRA

Jan 28, 2026

Target

$59.00

Current

$22.01

Performance

-29.18%

On Jan 28, 2026, Eliana Merle initiated coverage on TYRA with a Overweight rating and target of 59. The Buy call has yet to be validated as shares remain 36.99 away from the target.

PTCT

Jan 28, 2026

Target

$119.00

Current

$67.57

Performance

-10.62%

Eliana Merle issued a Overweight recommendation for PTCT on Jan 28, 2026, price target set at 119. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

IVA

Jan 28, 2026

Target

$18.00

Current

$4.45

Performance

-34.85%

On Jan 28, 2026, IVA was evaluated by Eliana Merle, who gave a Overweight rating and target of 18. Investors saw limited payoff as shares fell short of the 18 target.

FDMT

Jan 28, 2026

Target

$33.00

Current

$14.18

Performance

64.88%

Eliana Merle rated FDMT as Overweight on Jan 28, 2026, setting a price target of 33. The call has proven timely, with shares rising 64.88% toward the price target of 33.

BBIO

Jan 28, 2026

Target

$80.00

Current

$76.08

Performance

-1.82%

On Jan 28, 2026, BBIO was given a Overweight rating by Eliana Merle, with a target price of 80. The stock traded sideways with a -1.82% move, keeping the bullish thesis unresolved.

ALT

Aug 13, 2025

Target

$24.00

Current

$3.35

Performance

-10.43%

ALT received a Buy rating from Eliana Merle on Aug 13, 2025, aiming for 24. The rating hasn’t played out as hoped, with the stock trading 10.43% below expectations.

ANAB

Aug 12, 2025

Target

$20.00

Current

$55.70

Performance

176.98%

On Aug 12, 2025, Eliana Merle published a Neutral outlook on ANAB, with a target of 20. The Hold call missed some of the bullish momentum as shares advanced toward 20.

RAPT

Aug 12, 2025

Target

$9.00

Current

$58.01

Performance

432.16%

Eliana Merle on Aug 12, 2025 assigned RAPT a Neutral rating, with a price target of 9. Shares outperformed expectations, climbing 432.16% despite the neutral view.

SRPT

Jul 21, 2025

Target

$12.00

Current

$22.02

Performance

65.32%

On Jul 21, 2025, Eliana Merle reaffirmed SRPT with a Neutral rating, targeting 12. Market strength beyond 22.02 went further than the conservative outlook suggested.

PROK

Jul 15, 2025

Target

$8.00

Current

$1.85

Performance

-45.10%

PROK was rated Buy by Eliana Merle on Jul 15, 2025, with a price objective of 8. This case shows how bullish projections can fail, with the stock now below 1.85.

CVAC

Jun 26, 2025

Target

$5.50

Current

$4.66

Performance

-13.70%

On Jun 26, 2025, Eliana Merle initiated coverage on CVAC with a Neutral rating and target of 5.5. The rating matched the stock’s inability to hold above 4.66.

ETNB

Jan 31, 2025

Target

$38.00

Current

$14.84

Performance

54.58%

Eliana Merle issued a Buy recommendation for ETNB on Jan 31, 2025, price target set at 38. Investors following the Buy call captured upside momentum, with shares now at 14.84.

AKRO

Jan 31, 2025

Target

$109.00

Current

$54.65

Performance

1.05%

On Jan 31, 2025, AKRO was evaluated by Eliana Merle, who gave a Buy rating and target of 109. So far, the Buy call awaits clearer momentum, with shares flat at 54.65.

ZNTL

Jan 28, 2025

Target

$2.20

Current

$3.80

Performance

58.33%

Eliana Merle rated ZNTL as Neutral on Jan 28, 2025, setting a price target of 2.2. Despite the Hold call, shares climbed 58.33% to 3.8, revealing unexpected momentum.

RVMD

Jan 08, 2025

Target

$71.00

Current

$207.68

Performance

367.54%

On Jan 08, 2025, RVMD was given a Buy rating by Eliana Merle, with a target price of 71. The stock rallied 367.54% after the rating, narrowing the gap to the target of 71 and validating the bullish stance.

BNTX

Sep 18, 2024

Target

$131.00

Current

$98.13

Performance

-15.13%

BNTX received a Neutral rating from Eliana Merle on Sep 18, 2024, aiming for 131. The Hold stance proved prudent, with the market softening by 15.13%.

Frequency Asked Questions

Who is Eliana Merle?

Eliana Merle is an analyst from Barclays specializing in the Healthcare sector.

What is Eliana Merle's success rate?

Eliana Merle currently has a success rate of +78.36%.

How many ratings has Eliana Merle issued?

Eliana Merle has issued 46 stock ratings so far.

What is the average return of Eliana Merle's calls?

Their stock ratings have generated an average return of +26.28%.

What is Eliana Merle's ranking?

Eliana Merle is ranked #1472 out of 4769 analysts.

What types of ratings does Eliana Merle give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Eliana Merle?

You can follow Eliana Merle by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Eliana Merle?

Their latest rating was a Buy on SGMT issued on 2026-09-09.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep